Form 4: Syros Pharmaceuticals Director Nancy A. Simonian Reports Stock Transactions
SEC Form 4 Filing
Director Nancy A. Simonian reported the vesting of restricted stock units and subsequent tax withholding, resulting in changes to her beneficial ownership of Syros Pharmaceuticals stock.
Summary
- On March 31, 2024, Nancy A. Simonian, a director of Syros Pharmaceuticals, reported the vesting of 6,000 restricted stock units (RSUs) from an award granted on February 15, 2022, and 39,566 RSUs from an award granted on February 16, 2023.
- These RSUs converted into common stock.
- Simonian also disposed of 14,052 shares on April 1, 2024, to cover tax withholding obligations at a price of $5.12 per share.
- Following these transactions, Simonian directly owns 131,658 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of insider transactions related to compensation.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to director compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| February 15, 2022 | Date of restricted stock unit award that vests in four equal annual installments commencing on March 31, 2023. |
| February 16, 2023 | Date of restricted stock unit award that vests in three equal annual installments commencing on March 31, 2024. |
| March 31, 2023 | First vesting date for the restricted stock unit award granted on February 15, 2022. |
| March 31, 2024 | Date of transaction: vesting of restricted stock units and conversion to common stock. |
| April 01, 2024 | Date of transaction: disposal of shares to cover tax withholding. |
| April 02, 2024 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Syros Pharmaceuticals, Insider Trading, Director, Simonian
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.